Surfactant Replacement Therapy in Preterm Infants: A European Survey

Anton H. van Kaam*, Anne P. De Jaegere, Dorine Borensztajn, Peter C. Rimensberger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Web of Science)


Exogenous surfactant is an undisputed treatment for neonatal respiratory distress syndrome but its efficacy is highly dependent on the treatment strategy. International guidelines have published recommendations on the optimal surfactant replacement strategy.To determine how evidence-based guidelines on surfactant replacement therapy are implemented in daily clinical practice.Data on surfactant replacement therapy, including preparation, dosing and timing, were collected in 173 European neonatal intensive care units (NICUs) by questionnaire and in a cohort of preterm infants mechanically ventilated on two separate predefined dates in these units.All NICUs used animal-derived surfactant in the treatment of respiratory distress syndrome, with Poractant being most widely used (86%). The most frequently used first dose was 100 mg/kg (58%) and 200 mg/kg (39%) and all NICUs allowed for repeat dosing. 39% of the NICUs claimed to use prophylactic treatment (2 h after birth. 43% of the infants received multiple doses.With the exception of surfactant timing, guidelines on surfactant replacement therapy seem to be implemented in daily clinical practice in European NICUs.
Original languageEnglish
Pages (from-to)71-77
Issue number1
Publication statusPublished - 2011


  • Surfactant
  • Preterm infant
  • Mechanical ventilation
  • Best practice guidelines

Cite this